Bitrus Yakubu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bitrus Yakubu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Dunkura Ali Umaru
Department of Biotechnology, Modibbo Adama University of Technology Yola, Adamawa State
1 shared publication- Emmanuel Tumininu Obishakin
National Veterinary Research Institute
1 shared publication J Nok Andrew
Department of Biochemistry, Ahmadu Bello University Zaria, Kaduna State
1 shared publicationO A Owolodun
Applied Molecular Biology Division, National Veterinary Research Institute, Vom, Plateau State
1 shared publication- Olajide Adewale Owolodun
Biotechnology Division, National Veterinary Research Institute, Vom 930001, Nigeria
1 shared publication - Pam Dachung Luka
National Veterinary Research Institute
1 shared publication
Latest Publications
- Open Access
- 30 July 2015
- Published by Academic Journals in Biotechnology and Molecular Biology Reviews
- Vol. 10 (3) , 19-38
The reoccurrence of H5N1 outbreaks necessitates the development of safe and effective influenza vaccine technologies for the prevention and control of avian influenza in Sub-Saharan Africa
Africa is experiencing reoccurrence of avian influenza outbreaks with huge negative impact on the economy of the continent as a result of high mortality rate and extreme contagiousness of the disease. The epidemiology of highly pathogenic avian influenza (HPAI) in Africa during the 2006-2008 outbreaks was complex and linked to movements of poultry commodities and wild birds. The peculiar risk factors, negative economic impact and the potential of being used as a biological weapon necessitates the development of a comprehensive control programme for the prevention or eradication of the disease. It is the opinion of this paper that development of new influenza vaccine technologies will provide affordable comprehensive control programmes for avian influenza prevention in Africa. To keep pace with the variability of the viruses, there is need for frequent redesign of avian influenza (AI) vaccines to match the circulating subtypes and on this is predicated the necessity of the development of influenza vaccine technology for a country, zone or region. The new vaccine technologies have been shown to have the potentials of giving vaccines with required criteria of purity, safety, efficacy, potency, low cost and short response time. The concept of most new vaccine technologies is biased towards removal of influenza virus from the system of vaccine development and at the same time obtaining more effective, potent and safe influenza vaccines. The new influenza vaccine technologies include gene-based, genomics-based, subunit, plant-based, VLPs and universal vaccine technologies. These technologies have the potential to provide vaccines that will not just be used as intervention strategies to lessen severity of the disease but as preventative vaccination. Also routine vaccination will not just be as a tool of last option in disease endemic areas, but one to prevent the disease. Key words: Technologies, avian influenza, vaccine, eradication, prevention, comprehensive, control, programme.
- 30 July 2015
- Published by Academic Journals in Biotechnology and Molecular Biology Reviews
- Vol. 10 (3) , 19-38
Open AccessThe reoccurrence of H5N1 outbreaks necessitates the development of safe and effective influenza vaccine technologies for the prevention and control of avian influenza in Sub-Saharan Africa
Africa is experiencing reoccurrence of avian influenza outbreaks with huge negative impact on the economy of the continent as a result of high mortality rate and extreme contagiousness of the disease. The epidemiology of highly pathogenic avian influenza (HPAI) in Africa during the 2006-2008 outbreaks was complex and linked to movements of poultry commodities and wild birds. The peculiar risk factors, negative economic impact and the potential of being used as a biological weapon necessitates the development of a comprehensive control programme for the prevention or eradication of the disease. It is the opinion of this paper that development of new influenza vaccine technologies will provide affordable comprehensive control programmes for avian influenza prevention in Africa. To keep pace with the variability of the viruses, there is need for frequent redesign of avian influenza (AI) vaccines to match the circulating subtypes and on this is predicated the necessity of the development of influenza vaccine technology for a country, zone or region. The new vaccine technologies have been shown to have the potentials of giving vaccines with required criteria of purity, safety, efficacy, potency, low cost and short response time. The concept of most new vaccine technologies is biased towards removal of influenza virus from the system of vaccine development and at the same time obtaining more effective, potent and safe influenza vaccines. The new influenza vaccine technologies include gene-based, genomics-based, subunit, plant-based, VLPs and universal vaccine technologies. These technologies have the potential to provide vaccines that will not just be used as intervention strategies to lessen severity of the disease but as preventative vaccination. Also routine vaccination will not just be as a tool of last option in disease endemic areas, but one to prevent the disease. Key words: Technologies, avian influenza, vaccine, eradication, prevention, comprehensive, control, programme.
- 27 June 2010
- Published by Springer Nature in Tropical Animal Health and Production
- Vol. 42 (8) , 1605-1610
Investigation of African swine fever in slaughtered pigs, Plateau state, Nigeria, 2004-2006
The occurrence of African swine fever (ASF) DNA in slaughtered pigs in the major pig producing areas of Plateau state over a 2-year period was investigated. Three hundred fifty-nine pig tissue samples from five local government councils (LGCs) were analyzed by clinical signs (C/S), postmortem (PM) lesions and polymerase chain reaction (PCR). The results of diagnosis made by C/S and PM were compared to results obtained by PCR. Out of the 359 abattoir samples, 13 (3.62%) were positive by examination of C/S and PM lesions while 346 (96.38%) were negative. Jos-north LGC had the highest occurrence of PCR positive samples (31 samples); Panyam in Mangu LGC had no positive result. PCR analysis identified 53 positive samples (14.76%); more than 40 were identified on the field. Of the samples, 306 were PCR negative, thus giving a true ASF status of pigs in Plateau state. Analysis of the results, variables involved in the ASF spread and predictable effects of such findings in the pig industry in Plateau state and Nigeria as a whole is discussed.
- 27 June 2010
- Published by Springer Nature in Tropical Animal Health and Production
- Vol. 42 (8) , 1605-1610
Investigation of African swine fever in slaughtered pigs, Plateau state, Nigeria, 2004-2006
The occurrence of African swine fever (ASF) DNA in slaughtered pigs in the major pig producing areas of Plateau state over a 2-year period was investigated. Three hundred fifty-nine pig tissue samples from five local government councils (LGCs) were analyzed by clinical signs (C/S), postmortem (PM) lesions and polymerase chain reaction (PCR). The results of diagnosis made by C/S and PM were compared to results obtained by PCR. Out of the 359 abattoir samples, 13 (3.62%) were positive by examination of C/S and PM lesions while 346 (96.38%) were negative. Jos-north LGC had the highest occurrence of PCR positive samples (31 samples); Panyam in Mangu LGC had no positive result. PCR analysis identified 53 positive samples (14.76%); more than 40 were identified on the field. Of the samples, 306 were PCR negative, thus giving a true ASF status of pigs in Plateau state. Analysis of the results, variables involved in the ASF spread and predictable effects of such findings in the pig industry in Plateau state and Nigeria as a whole is discussed.